RhoA is associated with invasion and lymph node metastasis in upper urinary tract cancer

被引:47
作者
Kamai, T
Kawakami, S
Koga, F
Arai, G
Takagi, K
Arai, K
Tsujii, T
Yoshida, KI
机构
[1] Dokkyo Univ, Sch Med, Dept Urol, Mibu, Tochigi 3210293, Japan
[2] Tokyo Metropolitan Tama Geriatr Hosp, Tokyo, Japan
关键词
rho small GTPase; metastasis; renal pelvis; ureter; cancer;
D O I
10.1046/j.1464-410X.2003.03063.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To assess the roles of RhoA small GTPase (RhoA) in upper urinary tract cancer by analysing the mRNA and protein levels of RhoA. PATIENTS AND METHODS The mRNA and protein levels of RhoA in matched sets of tumour, non-tumour and metastatic lymph node tissues of surgical specimens were analysed in 47 consecutive patients with renal pelvic/ureteric cancer, using the polymerase chain reaction after reverse transcription and Western blotting. The relationship between mRNA and protein levels of RhoA in tumour tissues and the clinicopathological features of the patients was also assessed. RESULTS The mRNA levels of RhoA and RhoA protein were greater in tumour and metastatic lymph node tissues than in non-tumour tissues (all P < 0.001). The expression levels of RhoA mRNA and protein levels in primary tumours was related to poorly differentiated grade (both P < 0.05) and muscle invasion (P < 0.01 and < 0.001, respectively). Kaplan-Meier plots of survival in patients with low or high RhoA showed that high mRNA and protein levels were associated with a shorter disease-free (P < 0.01) and overall survival (P < 0.001). Multivariate analysis using the Cox proportional hazards model showed that a high RhoA protein level was an independent prognostic factor, second to stage, in disease-free and overall survival (both P < 0.05). CONCLUSIONS These findings suggest that RhoA is involved in the invasion and metastasis of upper urinary tract cancer, indicating that RhoA may be a useful prognostic factor in this disease.
引用
收藏
页码:234 / 238
页数:5
相关论文
共 19 条
[1]  
ADAMSON P, 1992, J BIOL CHEM, V267, P20033
[2]  
Adamson P, 1999, J IMMUNOL, V162, P2964
[3]   PRIMARY CARCINOMA OF URETER - A REPORT OF 102 NEW CASES [J].
BLOOM, NA .
JOURNAL OF UROLOGY, 1970, 103 (05) :590-+
[4]   LONG-TERM FOLLOW-UP IN PATIENTS TREATED WITH METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN (M-VAC) FOR TRANSITIONAL CELL-CARCINOMA OF URINARY-BLADDER - CAUSE FOR CONCERN [J].
CONNOR, JP ;
RAPOPORT, F ;
OLSSON, CA ;
SAWCZUK, IS ;
BENSON, MC .
UROLOGY, 1989, 34 (06) :353-356
[5]  
del Peso L, 1997, ONCOGENE, V15, P3047
[6]   THE RAS-RELATED SMALL GTP-BINDING PROTEIN RHOB IS IMMEDIATE-EARLY INDUCIBLE BY DNA-DAMAGING TREATMENTS [J].
FRITZ, G ;
KAINA, B ;
AKTORIES, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (42) :25172-25177
[7]  
Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO
[8]  
2-B
[9]   Rho GTPases and the actin cytoskeleton [J].
Hall, A .
SCIENCE, 1998, 279 (5350) :509-514
[10]   Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase [J].
Imamura, F ;
Mukai, M ;
Ayaki, M ;
Akedo, H .
JAPANESE JOURNAL OF CANCER RESEARCH, 2000, 91 (08) :811-816